Rovunaptabin

N/A

Report date: 2025/03/13 09:24:27

Base Information

Drug NameRovunaptabin
Drug Alias NameBC 007BC-007
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer
Mechanisms of ActionImmunomodulatorsVirus replication inhibitors
TargetsNot applicable
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeHeart FailureCardiomyopathy, Dilated
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySerbiaAustriaGermany +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBerlin Cures Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBerlin Cures Gmbh
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeHeart FailureCardiomyopathy, Dilated
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A